[go: up one dir, main page]

TW200505435A - Treatment of ocular disorders - Google Patents

Treatment of ocular disorders

Info

Publication number
TW200505435A
TW200505435A TW093101868A TW93101868A TW200505435A TW 200505435 A TW200505435 A TW 200505435A TW 093101868 A TW093101868 A TW 093101868A TW 93101868 A TW93101868 A TW 93101868A TW 200505435 A TW200505435 A TW 200505435A
Authority
TW
Taiwan
Prior art keywords
treatment
ocular disorders
disorders
aminoaliphatyl
oxepines
Prior art date
Application number
TW093101868A
Other languages
English (en)
Inventor
George N Lambrou
Elisabeth Latour
Peter Waldmeier
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0302091A external-priority patent/GB0302091D0/en
Priority claimed from GB0302436A external-priority patent/GB0302436D0/en
Priority claimed from GB0323829A external-priority patent/GB0323829D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TW200505435A publication Critical patent/TW200505435A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Epoxy Compounds (AREA)
TW093101868A 2003-01-29 2004-01-28 Treatment of ocular disorders TW200505435A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0302091A GB0302091D0 (en) 2003-01-29 2003-01-29 Use of organic compounds
GB0302436A GB0302436D0 (en) 2003-02-03 2003-02-03 Use of organic compounds
GB0323829A GB0323829D0 (en) 2003-10-10 2003-10-10 Use of organic compounds

Publications (1)

Publication Number Publication Date
TW200505435A true TW200505435A (en) 2005-02-16

Family

ID=32830359

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093101868A TW200505435A (en) 2003-01-29 2004-01-28 Treatment of ocular disorders

Country Status (5)

Country Link
US (1) US20060100269A1 (zh)
EP (1) EP1589963A1 (zh)
JP (1) JP2006516580A (zh)
TW (1) TW200505435A (zh)
WO (1) WO2004066993A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1757284A1 (en) 2005-08-25 2007-02-28 Santhera Pharmaceuticals (Schweiz) AG Use of N-(dibenz(b,f)oxepin-10ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of muscular dystrophy
EP1842539A1 (en) 2006-04-05 2007-10-10 Santhera Pharmaceuticals (Schweiz) AG Use of N- (dibenz(b,f)oxepin-10-ylmethyl)N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of congenital muscular dystrophy or myopathy resulting from collagen VI deficiency
JP4709918B2 (ja) * 2009-09-25 2011-06-29 株式会社東芝 リモコン装置
WO2014120885A1 (en) 2013-01-30 2014-08-07 The Johns Hopkins University Treatment of drug abuse by preventing gapdh nitrosylation
KR101965763B1 (ko) * 2016-08-19 2019-04-04 니켐 파인 테크놀로지 컴퍼니 리미티드 화합물 및 이를 이용하는 유기 전자 소자

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0726265B1 (de) * 1995-02-08 2001-07-25 Novartis AG Antineurodegenerativ wirksame 10-Aminoaliphatyl-dibenz- b,f oxepine
AR008371A1 (es) * 1996-05-30 2000-01-19 Novartis Ag Una sal de adicion con acido de una 10-aminoalifatil-dibenz[b,f],oxepina, su empleo; procedimiento para su elaboracion, una 10-aminoalifatil-dibenz[b,f]oxepina, una preparacion farmaceutica que contiene dicha sal o dicha oxepina y un procedimiento para el tratamiento de enfermedades neurodegenerativ

Also Published As

Publication number Publication date
US20060100269A1 (en) 2006-05-11
EP1589963A1 (en) 2005-11-02
JP2006516580A (ja) 2006-07-06
WO2004066993A1 (en) 2004-08-12

Similar Documents

Publication Publication Date Title
TW200510301A (en) Novel compounds
TW200510303A (en) Novel compounds
TW200407305A (en) Novel compounds
MXPA04001940A (es) Tratamiento para desordenes del sistema nervioso central.
MXPA06014721A (es) Derivados de alquinilo como moduladores de los receptores de glutamato metabotropico.
MXPA05011643A (es) 5,7-diaminopirazolo[4,3-d]pirimidinas en el tratamiento de hipertension.
GB0510141D0 (en) Novel compounds B3
TW200612892A (en) Novel compounds
SE0203713D0 (sv) Novel compounds
TW200509892A (en) Novel aminobenzophenone compounds
TW200508201A (en) Novel process for the preparation of roflumilast
WO2005046603A3 (en) Pyridine compounds
UA83194C2 (ru) Производные пиримидина и их применение как модуляторов св2
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
MXPA05013553A (es) Pirrolodihidroisoquinolinas como inhibidores de pde10.
GB0510143D0 (en) Novel compounds A1
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
PL371127A1 (en) 6-aminomorphinane derivatives, method for the production and use thereof
DE602006016449D1 (zh)
MX2007011847A (es) Derivados de pirimidindiona como antagonistas del receptor de procineticina 2.
TW200504402A (en) Antimicrobial lenses, processes to prepare them and methods of their use
MX2008002166A (es) Compuestos y composiciones como mimeticos de trombopoietina (tpo).
EP1441724B8 (en) Methods of increasing endogenous testosterone levels
TW200505435A (en) Treatment of ocular disorders